Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 6Sunitinib 3Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Injections 2recombinant interferon alpha 2b-like protein 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1fludarabine phosphate 1cabozantinib 1batifiban 1abemaciclib 1X-Rays 1Sorafenib 1Phantoms, Imaging 1PM 01183 1Oxaliplatin 1Leucovorin 1Interleukin-13 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cryotherapy 1Biopsy 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × batifiban × NET × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡